Chemokine Pathways in Cutaneous Melanoma: Their Modulation by Cancer and Exploitation by the Clinician.
Chemokine Pathways in Cutaneous Melanoma: Their Modulation by Cancer and Exploitation by the Clinician.
复制标题
DOI：
10.3390/cancers13225625
复制
发表时间：
2021-11-10
期刊：
影响因子：
5.2
通讯作者：
Lacy KE
中科院分区：
文献类型：
--
作者：
Adams R;Moser B;Karagiannis SN;Lacy KE
尽管过去十年免疫疗法取得了重大进展，但英国每年仍有 2500 人因黑色素瘤死亡。改善黑色素瘤治疗的临床需求仍然未得到满足。黑色素瘤被称为“原型免疫原性肿瘤”，具有致密的免疫浸润。趋化因子是趋化细胞因子，对于所有免疫细胞的定位至关重要。这篇综述概述了趋化因子网络的相互作用如何使黑色素瘤肿瘤存活、生长、转移和逃避抗癌免疫反应。通过更好地了解黑色素瘤如何利用趋化因子途径，可能会揭示新的治疗靶点。全球皮肤恶性黑色素瘤的发病率正在上升，并且预计将继续上升。过去十年免疫疗法的进展表明，操纵肿瘤的免疫细胞区室是抗击癌症的宝贵武器。然而，治疗的局限性仍然存在。皮肤黑色素瘤病变的特点是密集的细胞浸润，由趋化因子协调，控制所有免疫细胞的定位。黑色素瘤能够利用趋化因子途径优先招募细胞，这有助于它们的生长、存活、侵袭和转移，并增强它们逃避抗癌免疫反应的能力。除此之外，趋化因子信号传导可以直接影响血管生成、侵袭、淋巴结和远端转移，包括上皮间质转化样过程和跨内皮迁移。了解趋化因子、癌细胞和免疫细胞的相互作用可能会揭示黑色素瘤治疗的未来途径，即：识别患者分层的生物标志物，增强当前和新兴疗法的效果，并设计针对趋化因子途径的特定治疗方法，目的是降低黑色素瘤的致病性、转移潜力，并增强免疫细胞介导的癌症杀伤作用。趋化因子网络可以提供选择性和特定的靶标，如果将其纳入当前的治疗方案中，则有可能改善患者的治疗结果。
Despite significant advances in immunotherapy seen in the last decade, melanoma accounts for 2500 deaths a year in the UK. There remains an unmet clinical need to improve melanoma treatment. Melanoma is known as the “archetypal immunogenic tumour”, with a dense immune infiltrate. Chemokines are chemoattractant cytokines, essential for the positioning of all immune cells. This review outlines how the interplay of chemokine networks can enable melanoma tumours to survive, grow, metastasise, and evade anticancer immune responses. By better understanding how melanomas can exploit chemokine pathways, new targets to therapy may be revealed. The incidence of cutaneous malignant melanoma is rising globally and is projected to continue to rise. Advances in immunotherapy over the last decade have demonstrated that manipulation of the immune cell compartment of tumours is a valuable weapon in the arsenal against cancer; however, limitations to treatment still exist. Cutaneous melanoma lesions feature a dense cell infiltrate, coordinated by chemokines, which control the positioning of all immune cells. Melanomas are able to use chemokine pathways to preferentially recruit cells, which aid their growth, survival, invasion and metastasis, and which enhance their ability to evade anticancer immune responses. Aside from this, chemokine signalling can directly influence angiogenesis, invasion, lymph node, and distal metastases, including epithelial to mesenchymal transition-like processes and transendothelial migration. Understanding the interplay of chemokines, cancer cells, and immune cells may uncover future avenues for melanoma therapy, namely: identifying biomarkers for patient stratification, augmenting the effect of current and emerging therapies, and designing specific treatments to target chemokine pathways, with the aim to reduce melanoma pathogenicity, metastatic potential, and enhance immune cell-mediated cancer killing. The chemokine network may provide selective and specific targets that, if included in current therapeutic regimens, harbour potential to improve outcomes for patients.
登录
查看更多内容
影响因子：
11.2
作者：
Caunt, M;Hu, L;Karpatkin, S
通讯作者：
Karpatkin, S
基线嗜中性粒细胞与淋巴细胞比率与经ipilmimab治疗的转移性黑色素瘤患者的结果有关。
影响因子：
8.8
作者：
Ferrucci PF;Gandini S;Battaglia A;Alfieri S;Di Giacomo AM;Giannarelli D;Cappellini GC;De Galitiis F;Marchetti P;Amato G;Lazzeri A;Pala L;Cocorocchio E;Martinoli C
通讯作者：
Martinoli C
DOI：
10.1111/j.1549-8719.2010.00074.x
发表时间：
2011-04
期刊：
Microcirculation (New York, N.Y. : 1994)
影响因子：
--
作者：
Emmett MS;Lanati S;Dunn DB;Stone OA;Bates DO
通讯作者：
Bates DO
影响因子：
--
作者：
Follo, Matilde Y;Manzoli, Lucia;Cocco, Lucio
通讯作者：
Cocco, Lucio
影响因子：
3.9
作者：
Fujimura, Taku;Sato, Yota;Aiba, Setsuya
通讯作者：
Aiba, Setsuya